Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.71 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.70 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL30758618 | 0.98 | RAB9A (0.96) | RAB9ANPC1MAPTSMN1; SMN2PTPN1 | |
| SCHEMBL23484358 | 0.94 | NPC1 (0.89) | RAB9ANPC1MAPTSMN1; SMN2PTPN1 | |
| SCHEMBL11936816 | 0.93 | RAB9A (0.86) | RAB9ANPC1MAPTSMN1; SMN2PTPN1 | |
| SCHEMBL178425 | 0.92 | RAB9A (0.85) | RAB9ANPC1MAPTSMN1; SMN2PTPN1 | |
| SCHEMBL14580374 | 0.90 | RAB9A (1.00) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL27181403 | 0.90 | RAB9A (1.00) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL12310125 | 0.90 | RAB9A (1.00) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL822378 | 0.90 | RAB9A (1.00) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL15214321 | 0.90 | RAB9A (1.00) | RAB9ANPC1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL126415 | 0.89 | PTPN1 (0.87) | RAB9ANPC1MAPTSMN1; SMN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116464-B | (E) -4- (pyridylformylhydrazono) -N-phenylbenzamide antitumor compounds | 中国医科大学 | 2022-09-13 | — | — | CN | claimed |
| EP-3303290-A1 | ROR GAMMA (RORY) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-04-11 | — | — | EP | claimed |
| EP-3303291-A1 | ROR GAMMA (ROR ) MODULATORS | Lead Pharma Holding B.V. (NL) | 2018-04-11 | — | — | EP | claimed |
| WO-2016193452-A1 | ROR GAMMA (RORγ) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | claimed |
| WO-2016193459-A1 | ROR GAMMA (RORY) MODULATORS | LEAD PHARMA CEL MODELS IP B.V. (NL) | 2016-12-08 | — | — | WO | claimed |
| EP-2726459-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | Institute for Hepatitis and Virus Research (US) | 2014-05-07 | — | — | EP | claimed |
| WO-2013006394-A1 | SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2013-01-10 | — | — | WO | claimed |
| CN-1934107-A | 2- (3-substituted aryl) amino-4-aryl-thiazoles as tyrosine kinase inhibitors | AB SCIENCE (FR) | 2007-03-21 | — | — | CN | claimed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | claimed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| EP-0620122-B1 | Thermosensitive recording material | NEW OJI PAPER CO LTD (JP) | 1996-03-13 | — | — | EP | claimed |
| US-5446010-A | Substrate sheet, thermosensitive colored image forming layer containing colorless dye precursor, binder, color developing agent having sulfonylureido group, aromatic amide sensitizer; storage stability | NEW OJI PAPER CO., LTD. (JP) | 1995-08-29 | — | — | US | claimed |
| EP-0620122-A1 | Thermosensitive recording material | NEW OJI PAPER CO., LTD. (JP) | 1994-10-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885NPC1 2649/4885MAPT 2771/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | RAB9A 1779/4885NPC1 2649/4885MAPT 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.